SOURCE: Aradigm Corporation

November 09, 2006 12:54 ET

Aradigm Corporation Third Quarter 2006 Earnings and Conference Call Notification

HAYWARD, CA -- (MARKET WIRE) -- November 9, 2006 -- Aradigm Corporation (NASDAQ: ARDM) will announce its third quarter 2006 financial results on Friday, November 10, 2006. The Company will host a live webcast and conference call at 4:30p.m Eastern Time/ 1:30 p.m. Pacific Time that same day.

Date:                 Friday, November 10, 2006
Time:                 4:30 pm Eastern, 1:30 pm Pacific
Internet:             The live webcast can be accessed at
Telephone:            1 (877) 788-8790
                      INTERNATIONAL CALLERS, DIAL +1 (706) 679-7281
Passcode:             1918889 or mention Dr. Igor Gonda as moderator
For those unable to listen to the live broadcast, a replay will be available under the Investors section of the company website or by dialing 1 (800) 642-1687 (U.S. domestic) or +1 (706) 645-9291 (international) and entering in the conference ID # 1918889 beginning approximately one hour after the completion of the call.

About Aradigm

Aradigm is an emerging specialty pharmaceutical company focused on the development and commercialization of a portfolio of drugs delivered by inhalation for the treatment of severe respiratory diseases by pulmonologists. Current activities include partnered and self-initiated development programs addressing the treatment of cystic fibrosis, pulmonary hypertension, asthma, inhalation anthrax infections and smoking cessation.

In addition, Aradigm's AERx insulin Diabetes Management System (iDMS), which has been licensed to Novo Nordisk for development and commercialization in return for royalties, is in Phase 3 testing for Type 1 and Type 2 diabetes. Under the agreements with Novo Nordisk, Novo Nordisk is responsible for all further clinical, manufacturing and commercial development, while Aradigm and Novo Nordisk continue to cooperate and share in technology development, as well as intellectual property development and defense. Novo Nordisk also remains a substantial shareholder and investor in Aradigm.

Additional information about Aradigm can be found at

Except for the historical information contained herein, this news release contains forward-looking statements that involve risk and uncertainties, including preclinical and clinical results, the timely availability and acceptance of new products, the impact of competitive products and pricing, the availability of funding from partners or capital markets, and the management of growth, as well as the other risks detailed from time to time in Aradigm Corporation's Securities and Exchange Commission (SEC) Filings, including the company's Annual Report on Form 10-K, and quarterly reports on Form 10-Q.

Aradigm and AERx are registered trademarks of Aradigm Corporation.

Contact Information

  • Contact:
    Investor Relations
    Aradigm Corporation
    (510) 265-9370